Correlation Between Verrica Pharmaceuticals and Zymeworks Common

Can any of the company-specific risk be diversified away by investing in both Verrica Pharmaceuticals and Zymeworks Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Verrica Pharmaceuticals and Zymeworks Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Verrica Pharmaceuticals and Zymeworks Common Stock, you can compare the effects of market volatilities on Verrica Pharmaceuticals and Zymeworks Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Verrica Pharmaceuticals with a short position of Zymeworks Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Verrica Pharmaceuticals and Zymeworks Common.

Diversification Opportunities for Verrica Pharmaceuticals and Zymeworks Common

0.68

Correlation Coefficient

Verrica Pharmaceuticals  Zymeworks Common

Poor diversification

The 3 months correlation between Verrica and Zymeworks is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Verrica Pharmaceuticals and Zymeworks Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zymeworks Common Stock and Verrica Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Verrica Pharmaceuticals are associated (or correlated) with Zymeworks Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zymeworks Common Stock has no effect on the direction of Verrica Pharmaceuticals i.e., Verrica Pharmaceuticals and Zymeworks Common go up and down completely randomly.

Pair Corralation between Verrica Pharmaceuticals and Zymeworks Common

Given the investment horizon of 90 days Verrica Pharmaceuticals is expected to under-perform the Zymeworks Common. In addition to that, Verrica Pharmaceuticals is 1.73 times more volatile than Zymeworks Common Stock. It trades about -0.11 of its total potential returns per unit of risk. Zymeworks Common Stock is currently generating about -0.06 per unit of volatility. If you would invest  1,451  in Zymeworks Common Stock on December 30, 2024 and sell it today you would lose (214.00) from holding Zymeworks Common Stock or give up 14.75% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Verrica Pharmaceuticals  vs.  Zymeworks Common Stock

Verrica Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Verrica Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Zymeworks Common Stock

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zymeworks Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Verrica Pharmaceuticals and Zymeworks Common

The main advantage of trading using opposite Verrica Pharmaceuticals and Zymeworks Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Verrica Pharmaceuticals position performs unexpectedly, Zymeworks Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zymeworks Common will offset losses from the drop in Zymeworks Common's long position.

The idea behind Verrica Pharmaceuticals and Zymeworks Common Stock pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.